These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 17284368)
21. [TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela]. Cañas M; Morán Y; Camargo ME; Rivero MB; Bohórquez A; Villegas V; Ramírez E; Rendón Y; Suárez A; Morales L; Useche E; Salazar S; Zambrano A; Ramírez A; Valderrama E; Briceño Z; Chiurillo MA Invest Clin; 2009 Jun; 50(2):153-61. PubMed ID: 19662811 [TBL] [Abstract][Full Text] [Related]
22. Analysis of the codon 72 polymorphism of TP53 and human papillomavirus infection in Iranian patients with prostate cancer. Salehi Z; Hadavi M J Med Virol; 2012 Sep; 84(9):1423-7. PubMed ID: 22825821 [TBL] [Abstract][Full Text] [Related]
23. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Kamali-Sarvestani E; Talei AR; Merat A Cancer Lett; 2004 Nov; 215(1):83-7. PubMed ID: 15374636 [TBL] [Abstract][Full Text] [Related]
24. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Bonafé M; Ceccarelli C; Farabegoli F; Santini D; Taffurelli M; Barbi C; Marzi E; Trapassi C; Storci G; Olivieri F; Franceschi C Clin Cancer Res; 2003 Oct; 9(13):4860-4. PubMed ID: 14581358 [TBL] [Abstract][Full Text] [Related]
25. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176 [TBL] [Abstract][Full Text] [Related]
26. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766 [TBL] [Abstract][Full Text] [Related]
27. A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast. Schagdarsurengin U; Seidel C; Ulbrich EJ; Kölbl H; Dittmer J; Dammann R Int J Oncol; 2005 Jul; 27(1):185-91. PubMed ID: 15942659 [TBL] [Abstract][Full Text] [Related]
28. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356 [TBL] [Abstract][Full Text] [Related]
29. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Kalemi TG; Lambropoulos AF; Gueorguiev M; Chrisafi S; Papazisis KT; Kotsis A Cancer Lett; 2005 May; 222(1):57-65. PubMed ID: 15837541 [TBL] [Abstract][Full Text] [Related]
30. Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Zhuo XL; Li Q; Zhou Y; Cai L; Xiang ZL; Yuan W; Zhang XY Arch Med Res; 2009 Oct; 40(7):625-34. PubMed ID: 20082880 [TBL] [Abstract][Full Text] [Related]
31. TP53 PIN3 polymorphism associated with breast cancer risk in Iranian women. Faghani M; Ghasemi FM; Nikhbakht M; Salehi M Indian J Cancer; 2011; 48(3):298-302. PubMed ID: 21921327 [TBL] [Abstract][Full Text] [Related]
32. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Santos AM; Sousa H; Catarino R; Pinto D; Pereira D; Vasconcelos A; Matos A; Lopes C; Medeiros R Cancer Genet Cytogenet; 2005 Jun; 159(2):143-7. PubMed ID: 15899386 [TBL] [Abstract][Full Text] [Related]
33. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Buller RE; Sood A; Fullenkamp C; Sorosky J; Powills K; Anderson B Cancer Gene Ther; 1997; 4(4):239-45. PubMed ID: 9253509 [TBL] [Abstract][Full Text] [Related]
34. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Nordgard SH; Ritchie MD; Jensrud SD; Motsinger AA; Alnaes GI; Lemmon G; Berg M; Geisler S; Moore JH; Lønning PE; Børresen-Dale AL; Kristensen VN Pharmacogenet Genomics; 2007 Feb; 17(2):127-36. PubMed ID: 17301692 [TBL] [Abstract][Full Text] [Related]
35. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. Bau DT; Tsai MH; Lo YL; Hsu CM; Tsai Y; Lee CC; Tsai FJ Anticancer Res; 2007; 27(3B):1559-64. PubMed ID: 17595776 [TBL] [Abstract][Full Text] [Related]
36. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995 [TBL] [Abstract][Full Text] [Related]
37. TP53 codon 72 polymorphism in oral squamous cell carcinoma. Drummond SN; De Marco L; Pordeus Ide A; Barbosa AA; Gomez RS Anticancer Res; 2002; 22(6A):3379-81. PubMed ID: 12530090 [TBL] [Abstract][Full Text] [Related]
38. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Tan XL; Popanda O; Ambrosone CB; Kropp S; Helmbold I; von Fournier D; Haase W; Sautter-Bihl ML; Wenz F; Schmezer P; Chang-Claude J Breast Cancer Res Treat; 2006 Jun; 97(3):255-62. PubMed ID: 16331344 [TBL] [Abstract][Full Text] [Related]
39. MDR1 C3435T polymorphism in patients with breast cancer. Turgut S; Yaren A; Kursunluoglu R; Turgut G Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460 [TBL] [Abstract][Full Text] [Related]
40. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]